Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Raltegravir vs Boosted PIs in Treatment-Naive Patients
- The phase III ACTG A5257 trial compared atazanavir + ritonavir, darunavir + ritonavir, and raltegravir, each in combination with emtricitabine/tenofovir DF, in treatment-naive patients[Lennox 2014]
- The primary endpoint, time to virologic failure, was equivalent with all 3 regimens
- Using a preplanned composite endpoint of tolerability and virologic failure, the raltegravir arm was superior to both the atazanavir + ritonavir and darunavir + ritonavir arms, and the darunavir + ritonavir arm was superior to the atazanavir + ritonavir arm
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content